Phenotypes associated with this allele

• Allele Symbol: Mst1r^tm1.1Sew
• Allele Name: targeted mutation 1.1, Susan E Waltz
• Allele ID: MGI:2386421
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Mst1r^tm1.1Sew/Mst1r^tm1.1Sew	involves: 129/Ola * CD-1 * NIH Black Swiss	MGI:3027822

Genotype
MGI:3027822

hm1

• Allelic Composition: Mst1r^tm1.1Sew/Mst1r^tm1.1Sew
• Genetic Background: involves: 129/Ola * CD-1 * NIH Black Swiss

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

abnormal ovary morphology ( J:75503 )

♀ • epithelial hyperplasia

small ovary ( J:75503 )

♀

immune system

abnormal macrophage physiology ( J:75503 )

• reduced peritoneal macrophage activation, assessed by morphological changes, after stimulation with hepatocyte growth factor

• reduced production of NO by peritoneal macrophages after stimulation with LPS or IFN-g when in the presence of hepatocyte growth factor

abnormal type IV hypersensitivity reaction ( J:75503 )

• increased edema in delayed type hypersensitivity reaction, using dinitrofluorobenzene (DNFB) as the sensitizing agent

• influx of inflammatory cells to site of contact was similar to controls, however

increased acute inflammation ( J:75503 )

• increased edema at site of cutaneous irritant exposure

• influx of inflammatory cells to site of contact was similar to controls, however

increased susceptibility to endotoxin shock ( J:75503 )

• more susceptible to LPS-induced death than littermate controls

reproductive system

abnormal ovary morphology ( J:75503 )

♀ • epithelial hyperplasia

small ovary ( J:75503 )

♀

decreased superovulation rate ( J:85748 )

♀ • decrease ovulation upon hormonal stimulation

hematopoietic system

abnormal macrophage physiology ( J:75503 )

• reduced peritoneal macrophage activation, assessed by morphological changes, after stimulation with hepatocyte growth factor

• reduced production of NO by peritoneal macrophages after stimulation with LPS or IFN-g when in the presence of hepatocyte growth factor